Medeze Group
Medeze Group is a Thailand-based stem cell banking and regenerative medicine company that collects, isolates, cryopreserves, and cultivates mesenchymal, hematopoietic, adipose-derived, and hair follicle stem cells, plus NK cell immune services, serving individual consumers across six Southeast Asian countries.
- Company typePublic
- Founded2010
- HeadquartersBangkok, Thailand
- Headcount51–100
- GTM typeB2C
- OfferingServices
Medeze Group firmographics
Firmographics- Name
- Medeze Group
- Legal name
- MEDEZE Group Public Company Limited (บริษัท เมดีซ กรุ๊ป จำกัด (มหาชน))
- Website
- https://medezegroup.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Medeze Group is a Thailand-based stem cell banking and regenerative medicine company that collects, isolates, cryopreserves, and cultivates mesenchymal, hematopoietic, adipose-derived, and hair follicle stem cells, plus NK cell immune services, serving individual consumers across six Southeast Asian countries.
- Ownership category
- akta.pro rank
Medeze Group industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), NK Cell Therapies (HLAAABAD)
Keywords
Where Medeze Group is headquartered
LocationHeadquarters
- HQ city
- Bangkok
- HQ country
- Thailand
- HQ region
- Asia
Offices6 records
Markets served
Medeze Group business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Stem Cell Banking Services: One-time collection and long-term storage fees for stem cells from cord blood, cord tissue, and adipose tissue. Services are priced as packages starting from 69,000 THB for cord blood banking. Revenue is generated through upfront collection/processing fees combined with ongoing storage fees over the contracted storage period.
- NK Cell Services: NK Cell screening (NK Test) and NK Cell banking with cultivation using the Osaki Method. These services provide immune capacity assessment and highly active NK cell therapy for cancer prevention and immune strengthening.
- Hair Follicle Cell Banking: Hair follicle stem cell banking service using proprietary extraction and cryopreservation technology, a niche offering requiring minimal hair follicle extraction compared to traditional methods.
- Medical Wellness Services: Regenerative medicine and anti-aging services including precision medicine consultations, ATMPs Sandbox clinical programs, and longevity-focused healthcare solutions positioned for commercialization by 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Cord Blood Stem Cell Banking - starting price |
| One time/ perpetual license | Pay-as-you-go | Adipose Tissue Stem Cell Banking - starting price |
| One time/ perpetual license | Pay-as-you-go | Adipose Tissue Stem Cell Banking (C-Section) - starting price |
| One time/ perpetual license | Pay-as-you-go | Cord Tissue Stem Cell Banking |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Medeze Group product offering
Product offeringCore offering
Medeze Group provides stem cell banking services collecting, isolating, and cryopreserving stem cells from cord blood, cord tissue, adipose tissue, and hair follicles for newborns and adults. The company also offers NK Cell immune screening and Highly Active NK Cell therapy (Osaki Method), as well as hair follicle stem cell banking under the Medeze Hair Renaissance brand. All services operate under ISO 9001:2015 and AABB international accreditation standards from the Thailand headquarters.
Product overview
MEDEZE Group is a healthcare company offering a portfolio of stem cell banking and regenerative medicine services. The core offering is MEDEZE STEM CELL, which provides multiple stem cell banking services from various sources (cord blood, cord tissue, adipose tissue, and hair follicles) for both newborns and adults. This is complemented by MEDEZE NK for immune cell services (NK Test screening and Osaki Method-based cultivation), and MEDEZE HAIR RENAISSANCE for specialized hair follicle stem cell banking. A subsidiary brand, MEDEZE Cosmeceutical, offers skincare products utilizing growth factors from stem cells. The company's research arm (MEDEZE Research & Development) drives innovation in regenerative medicine applications including cornea production, cancer targeting, and osteoarthritis treatment. All services operate under international quality standards including ISO 9001:2015 and AABB accreditation.
Differentiator
Problem solved
Functional benefit
Brands
- MEDEZE STEM CELL: Stem cell banking services covering cord blood, cord tissue, adipose tissue, and hair follicle stem cell collection, isolation, and cryopreservation.
- MEDEZE NK
- MEDEZE Hair Renaissance
Products and services
- MEDEZE STEM CELL (Cord Blood, Cord Tissue, Adipose Tissue Banking) Comprehensive stem cell banking service covering Hematopoietic Stem Cells (HSC) from cord blood, Mesenchymal Stem Cells (MSC) from placenta/cord tissue, and Mesenchymal Stem Cells (ADSC) from adipose tissue. Includes AXP AutoXpress automated isolation, closed-system sterile processing, and cryopreservation at -196°C with viability up to 60 years. Designed for expecting parents banking for newborns and adults banking for future regenerative medicine.
- MEDEZE NK (NK Cell Screening and Therapy) Natural Killer (NK) Cell services including the NK Activity Test for immune capacity screening, NK Cell banking, and Highly Active NK Cell Therapy cultivated using the Osaki Method from Japan. Designed for individuals seeking immune system assessment and enhancement, cancer prevention, and viral defense. The Osaki Method maximizes NK cell potency for immunotherapy applications.
- MEDEZE HAIR RENAISSANCE (Hair Follicle Stem Cell Banking) Proprietary hair follicle stem cell banking service that preserves hair follicle cells for future hair restoration treatments. Requires only approximately 50 hair follicles for extraction (compared to ~3,000 required by traditional hair transplant methods), performed by specialized physicians with laboratory-grade cryopreservation. Designed for individuals interested in innovative, minimally invasive alternatives to traditional hair transplant procedures.
Quantifiable outcome
- Up to 98.7% stem cell isolation accuracy using AXP AutoXpress Platform
- +5 more outcomes
Companies that use Medeze Group
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Medeze Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Medeze Group partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, minor and moderate.
- Thailand Ministry of Public Health (ATMPs Sandbox)coreMEDEZE is the sole private sector participant in Thailand's ATMPs Sandbox program, a regulatory sandbox initiative by the Ministry of Public Health for developing advanced cell therapies. Pilot sites include Bangrak Medical Center (Bangkok) and Vachira Phuket Hospital, focusing on Stem Cell Therapy and NK Cell Immunotherapy for 4 disease areas (osteoarthritis, anti-aging, degenerative disc disease, skin rejuvenation).
- Dr. Junichi Masuyama / New City Osaki Clinic, JapancoreMEDEZE partners with Dr. Junichi Masuyama, creator of the Osaki Method for Highly Active NK Cell Therapy. Dr. Masuyama serves as Advisory Board member for MEDEZE NK Cell, providing expertise in NK cell cultivation for cancer immunotherapy and immune strengthening applications.
- 30+ Partner HospitalsminorMEDEZE has established partnerships with more than 30 hospitals, providing stem cell banking services and access to regenerative medicine treatments for clients referred through hospital networks.
- Suranaree University of Technology (SUT)moderatePartnership with Suranaree University of Technology under Prof. Dr. Rangsun Parnpai, focusing on embryonic stem cell research and cloning, as well as corneal production from adipose-derived mesenchymal stem cells (animal trial stage with Chulalongkorn University Veterinary Faculty).
- Phramongkutklao HospitalmoderateCollaboration with Phramongkutklao Hospital for applying stored adipose-derived stem cells in osteoarthritis treatment research.
- Chulalongkorn University Veterinary FacultymoderatePartnership for corneal production research from stem cells, currently in animal trial stage at Chulalongkorn University's Veterinary Faculty.
- AXP AutoXpress Platform (ThermoGenesis/Terumo)coreMEDEZE uses the AXP AutoXpress Platform for automated isolation of Hematopoietic Stem Cells from cord blood, achieving up to 98.7% cell recovery rates. This automated technology reduces contamination risk and human error in the cell isolation process.
- Frost & SullivanminorFrost & Sullivan provides ongoing market recognition and industry analyst awards to MEDEZE, including Southeast Asia Company of the Year 2025 and multiple consecutive Thailand Stem Cell Banking Company of the Year awards.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Medeze Group competitors and assessment
Company assessmentDirect peers
- Cells4Life: UK-based stem cell bank offering cord blood and tissue banking services to families. Comparable to MEDEZE on DTC consumer banking model, expectant parent focus, multi-source collection, and long-term cryopreservation service offerings.
- Cryo-Cell International: US-listed cord blood and tissue bank offering direct-to-consumer stem cell banking services. Directly comparable to MEDEZE on business model (collection, processing, long-term cryopreservation), customer segments (expectant parents and families), and recurring storage revenue, though operating in North America rather than Southeast Asia.
- Smart Cells International: UK-based stem cell banking company focused on cord blood and tissue storage for families and expectant parents. Directly comparable on DTC service model, geographic multi-market presence, and core cryopreservation offerings.
- Future Health Biobank: UK-headquartered stem cell banking company operating across multiple geographies, offering cord blood, cord tissue, and dental pulp stem cell storage. Direct peer based on multi-country DTC stem cell banking model, multi-source collection approach, and long-term cryopreservation service.
- StemCyte: US-headquartered umbilical cord blood bank with global operations across Asia (including India, Taiwan). Directly comparable to MEDEZE on cord blood banking model, multi-country Asian presence, and treatment-application positioning for hematopoietic and regenerative uses.
Broad incumbents
- Cord Blood Registry (CBR) by Generate Life Sciences: One of the largest US cord blood banks, now part of Generate Life Sciences which offers broader reproductive and newborn services. Comparable to MEDEZE on cord blood banking, expectant parent focus, and large-scale storage operations, but operates within a wider portfolio of family/newborn services.
- ViaCord (Revvity): US cord blood banking service owned by Revvity (formerly PerkinElmer), a large life sciences tools company. Comparable to MEDEZE on core stem cell banking service and expectant parent customer base, but operates as a smaller unit within a much larger life sciences conglomerate with broader diagnostics and research offerings.
Regional players
- Esperite (formerly Cryo-Save): European-headquartered family stem cell bank with operations across multiple European, Asian, and African markets. Comparable to MEDEZE on multi-country DTC stem cell banking model and recurring storage revenue, but operates in a different geographic footprint.
Emerging players
- Stempeutics Research: India-based stem cell therapy company developing allogeneic mesenchymal stem cell products for clinical use. Comparable to MEDEZE on stem cell therapy development and emerging market focus, but focused on therapeutic product development rather than consumer banking storage.
Others
- CellGenix: Germany-headquartered supplier of cell culture reagents and GMP-grade raw materials for cell and gene therapy manufacturing. Comparable to MEDEZE in the broader cell therapy ecosystem, but functions as an upstream supplier/technology enabler rather than a direct competitor in stem cell banking services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medeze Group social profiles
Digital presenceMedeze Group compliance and trust
Trust signalCompliance4 records
Medeze Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medeze Group leadership team
Management profileNumber of profiles
Profiles11 records
Medeze Group subsidiaries and ownership
Company hierarchySubsidiaries6 records
Medeze Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medeze Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medeze Group
What does Medeze Group do?
Medeze Group provides stem cell banking services collecting, isolating, and cryopreserving stem cells from cord blood, cord tissue, adipose tissue, and hair follicles for newborns and adults. The company also offers NK Cell immune screening and Highly Active NK Cell therapy (Osaki Method), as well as hair follicle stem cell banking under the Medeze Hair Renaissance brand. All services operate under ISO 9001:2015 and AABB international accreditation standards from the Thailand headquarters.
Is Medeze Group a public or private company?
Medeze Group is a public company. It is classified as unknown and is currently operating.
When was Medeze Group founded?
Medeze Group was founded in 2010. It employs 51 to 100 people.
Where is Medeze Group based?
Medeze Group is headquartered in Bangkok, Thailand, in the Asia region.
How does Medeze Group make money?
Four revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are NK Cell Services, hair Follicle Cell Banking and medical Wellness Services.
Who are Medeze Group's main competitors?
Direct peers on record are Cells4Life, Cryo-Cell International, Smart Cells International, Future Health Biobank and StemCyte. Broad incumbents are Cord Blood Registry (CBR) by Generate Life Sciences and ViaCord (Revvity). Esperite (formerly Cryo-Save) is listed as a regional player. Stempeutics Research is listed as an emerging player. CellGenix is listed as an others.
Does Medeze Group have an API?
No public API is recorded for Medeze Group.
What industry is Medeze Group in?
Medeze Group's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 621991 and its SIC code is 2836.